US Patent 10060921 Methods of treating transthyretin (TTR) mediated amyloidosis
Patent 10060921 was granted and assigned to Alnylam Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 10060921 Methods of treating transthyretin (TTR) mediated amyloidosis
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
